Biopharmaceuticals | Council For Citizens Against Government Waste

Biopharmaceuticals

CCAGW Urges California Senate to Oppose AB 1460

AB 1460 would change how the federal 340B Drug Pricing Program operates in the Golden State

The 340B Drug Pricing Program is Overdue for Reform

The 340B Drug Pricing Program has been used to inflate the profits of hospitals and pharmacies rather than providing savings.

CCAGW Urges Nevada Governor Joe Lombardo to Veto AB 259

AB 259 would allow price controls that would further distort the medical marketplace and fail to lower prices. 

This Week in Waste - April 18, 2025

This Week in Waste highlights how taxpayer dollars are being wasted and efforts to fight back against this waste. 

April 18, 2025 — Eric Maus 1745007259

Implementation of Drug Pricing EO Should Protect Innovation and IP

President Trump's EO addresses the dual objectives of lowering drug prices while promoting innovation and protecting IP

April 16, 2025 — Thomas Schatz 1744839152

CCAGW Urges Arkansas Legislators to Oppose House Bill 1150

HB 1150 would lead to the loss of more than 135 brick and mortar retail pharmacies in the state and eliminate associated cost-saving mail order and specialty pharmacy options.

CCAGW Urges Missouri Legislators to Oppose Senate Bills 45, 372, and 512

SB 45, SB 372, and SB 512 would create unnecessary regulatory barriers that will undermine the effectiveness of pharmacy benefit managers in Missouri and increase prescription drug costs for patients.

CCAGW Urges Missouri Legislators to Oppose House Bills 474 and 840

HB 474 and HB 840 would create unnecessary regulatory barriers that will undermine the effectiveness of pharmacy benefit managers in Missouri and increase prescription drug costs for patients.